ArticleFrontiers in oncology2026
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes a clinically rare case of early-stage primary extranodal marginal zone B-cell lymphoma of the prostate. A 73-year-old male presented with urinary hesitancy. Physical examination revealed mild prostatic enlargement. Prostate biopsy, immunohistochemistry, and genetic testing strongly suggested mucosa-associated lymphoid tissue (MALT) lymphoma. Bone marrow aspiration indicated no bone marrow involvement. Positron Emission Tomography-Computed Tomography (PET-CT) and Emission Computed Tomography (ECT) scans showed no evidence of involvement in other sites. Ultimately, the patient was definitively diagnosed with primary prostatic MALT lymphoma, Ann Arbor stage IE. He underwent external beam radiation therapy to the prostate, receiving a total dose of 3000 cGy delivered in 15 fractions. During radiotherapy, the patient experienced no significant adverse reactions. Following treatment, urinary obstruction symptoms markedly improved. Follow-up abdominal and urinary tract ultrasound examinations at 1week, 1month, and 4months post-radiotherapy showed marked tumor regression with no signs of recurrence. This report aims to share the treatment experience of this case, hoping to provide insights for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.